SEQUANA MEDICAL N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.39 EUR | -0.71% |
|
-3.47% | -65.25% |
Presentation Operator MessageOperator (Operator)Hello, and welcome to the Sequana 2022 Full Ye...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Sequana Medical N.V. is a commercial stage medical device company utilizing its proprietary alfapump® and DSR® (Direct Sodium Removal) technologies to develop innovative treatments for fluid overload in liver disease, malignant ascites and heart failure where diuretics are no longer effective. The alfapump is a fully-implanted, wireless device that automatically pumps fluid from the abdomen into the bladder, where it is removed naturally through urination. The alfapump is CE-marked for the management of refractory ascites due to liver cirrhosis and malignant ascites and has been granted breakthrough device designation by the US FDA with a North American pivotal study underway. DSR is a novel approach to manage sodium and fluid overload through use of a sodium-free infusate administered into the abdominal cavity. The alfapump DSR® combines DSR therapy with the proven alfapump platform and is in clinical development as potential treatment for decompensated heart failure patients.
Calendar
2024-05-22
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
3
Last Close Price
1.39
EUR
Average target price
5.967
EUR
Spread / Average Target
+329.26%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -65.25% | 53.29M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- SEQUA Stock
- News Sequana Medical N.V.
- Transcript : Sequana Medical NV, 2022 Earnings Call, Feb 09, 2023
